Levotuss (Levodropropizine)

Levodropropizine is used as an antitussive to manage coughs arising from irritation of the respiratory tract.

• Cough: Reduces frequency and severity of acute cough episodes.
• Dry cough: Suppresses non‑productive cough without causing sedation.
• Irritative cough: Alleviates cough caused by throat irritation or mild upper respiratory infections.

• Levodropropizine acts peripherally by inhibiting sensory C‑fibers in the respiratory mucosa, which decreases the afferent signals that trigger the cough reflex. Unlike opioid antitussives, it does not bind central µ‑opioid receptors, providing cough suppression with minimal central nervous system effects. The drug’s action is localized to the airway epithelium, leading to reduced excitability of the cough center indirectly. This peripheral mechanism allows effective cough control while preserving normal respiratory function.

Levodropropizine may be associated with several adverse reactions, which are generally mild but can be serious in rare cases.

Common Side Effects

• Nausea: mild stomach upset that may be transient and resolve without intervention.
• Dizziness: transient light‑headedness, often occurring shortly after dosing and usually subsiding quickly.
• Headache: occasional mild headache that does not typically require specific treatment.

Serious or Rare Side Effects

• Allergic reaction: rash, itching, swelling of the face, lips or tongue indicating hypersensitivity.
• Hepatic dysfunction: elevated liver enzymes or jaundice, requiring laboratory monitoring in susceptible individuals.
• Anaphylaxis: acute, potentially life‑threatening allergic response with respiratory distress and cardiovascular collapse.

When prescribing Levodropropizine, several precautionary measures should be observed to ensure safe use.

• Age limitation: use with caution in children under two years of age.
• Hepatic impairment: adjust use in patients with liver disease and monitor liver function.
• Renal impairment: consider dose adjustment in severe renal dysfunction.
• Concomitant CNS depressants: avoid combining with strong sedatives as additive effects may occur.
• Pregnancy and lactation: assess risk‑benefit before use; limited data available.
• Store at ambient temperature: keep below 25 °C, in original packaging, protected from moisture and direct sunlight.

Levodropropizine can interact with other medicines; awareness of major and moderate interactions helps prevent adverse outcomes.

Major Interactions (Avoid)

• MAO inhibitors: risk of enhanced serotonergic effects; avoid concurrent use.
• Strong CYP3A4 inhibitors: may increase plasma levels leading to toxicity.

Moderate Interactions (Monitor Closely)

• CNS depressants: additive sedation or dizziness; monitor patient response.
• Antihistamines: potential increase in antitussive effect; adjust dose if needed.
• Antacids: may alter absorption; separate administration times.